COSMOS Pharmaceutical (3349) Q3 2026 earnings summary

Executive summary

• Net sales for the nine months ended February 28, 2026, rose 7.7% year-over-year to ¥810,380 million, with operating profit up 1.2% to ¥32,021 million and profit attributable to owners of parent up 1.8% to ¥22,748 million.

• Store network expanded by 57 new stores, reaching a total of 1,662, despite challenging economic conditions and increased consumer price sensitivity.

Financial highlights

• Gross profit increased to ¥169,941 million from ¥159,208 million year-over-year.

• EBITDA for the period was ¥48,578 million, up 4.3% year-over-year.

• Basic earnings per share for the nine months was ¥287.02, with diluted EPS at ¥281.91.

• Comprehensive income for the period was ¥22,736 million, up 1.8% year-over-year.

Outlook and guidance

• Full-year net sales forecast is ¥1,057,000 million, up 4.5% year-over-year, with operating profit projected at ¥40,500 million and profit attributable to owners of parent at ¥31,000 million.

• No changes to previously announced financial results forecast.